SCHEMBL2954022

SCHEMBL2954022

Cc1ccccc1-n1c(=O)ccc2c(Br)c(C#N)sc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.37
KDM4E B2RXH2 5/20 0.37
HPGD P15428 3/20 0.37
GAA P10253 2/20 0.37
S1PR2 O95136 1/20 0.37
S1PR4 O95977 1/20 0.37
GLA P06280 1/20 0.37
S1PR1 P21453 1/20 0.37
LMNA P02545 4/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MGLL Q99685 1/20 0.35
RXFP1 Q9HBX9 2/20 0.33
HCAR1 Q9BXC0 1/20 0.33
MAPT P10636 2/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
BCAT1 P54687 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266756 0.85 ALDH1A1 (0.37) ALDH1A1KDM4EGAAS1PR4GLA
SCHEMBL2955709 0.85 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDGAAS1PR2
SCHEMBL2781979 0.82 ADORA1 (0.37) ALDH1A1KDM4EHPGDGAALMNA
SCHEMBL2955547 0.80 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDGAAGLA
SCHEMBL2952051 0.76 IDO1 (0.38) ALDH1A1KDM4EHPGDGAAS1PR2
SCHEMBL2959772 0.74 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDGAAS1PR2
SCHEMBL2960714 0.73 EP300 (0.37) ALDH1A1GAAL3MBTL1MEN1KMT2A
SCHEMBL2960302 0.73 KMT2A (0.37) ALDH1A1GAAL3MBTL1MEN1KMT2A
SCHEMBL2955895 0.71 MEN1 (0.35) ALDH1A1HPGDGAALMNAL3MBTL1
SCHEMBL1265636 0.70 ALDH1A1 (0.37) ALDH1A1KDM4EGAAS1PR4GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK ALDH1A1 1045/4885KDM4E 2174/4885HPGD 3282/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 ALDH1A1 717/4885KDM4E 2211/4885HPGD 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.